-$1.13 EPS Expected for Insmed Incorporated (INSM) This Quarter

Equities research analysts expect Insmed Incorporated (NASDAQ:INSM) to report ($1.13) earnings per share (EPS) for the current quarter, Zacks reports. Three analysts have made estimates for Insmed’s earnings. The lowest EPS estimate is ($1.16) and the highest is ($1.08). Insmed posted earnings per share of ($0.85) during the same quarter last year, which would suggest a negative year over year growth rate of 32.9%. The company is expected to issue its next earnings results on Friday, February 22nd.

According to Zacks, analysts expect that Insmed will report full-year earnings of ($4.16) per share for the current year, with EPS estimates ranging from ($4.19) to ($4.10). For the next year, analysts forecast that the company will report earnings of ($3.83) per share, with EPS estimates ranging from ($5.03) to ($2.79). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Insmed.

Insmed (NASDAQ:INSM) last issued its earnings results on Tuesday, October 30th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.08).

INSM has been the subject of a number of recent analyst reports. BidaskClub downgraded Insmed from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 19th. Goldman Sachs Group set a $25.00 price objective on Insmed and gave the company a “hold” rating in a research note on Wednesday, September 19th. Morgan Stanley boosted their target price on Insmed from $39.00 to $40.00 and gave the stock an “overweight” rating in a research note on Monday, October 1st. Credit Suisse Group lifted their price target on Insmed from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, October 1st. Finally, ValuEngine lowered Insmed from a “buy” rating to a “hold” rating in a research report on Tuesday, October 2nd. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Insmed currently has a consensus rating of “Buy” and a consensus target price of $30.43.

Shares of INSM opened at $22.70 on Friday. Insmed has a 52-week low of $11.31 and a 52-week high of $32.07. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of -7.85 and a beta of 1.93. The company has a debt-to-equity ratio of 1.07, a current ratio of 10.06 and a quick ratio of 10.06.

In other Insmed news, Director Melvin Md Sharoky bought 11,205 shares of the firm’s stock in a transaction dated Friday, November 9th. The stock was acquired at an average price of $16.34 per share, with a total value of $183,089.70. Following the completion of the transaction, the director now directly owns 231,794 shares in the company, valued at approximately $3,787,513.96. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO William Lewis bought 15,700 shares of the firm’s stock in a transaction dated Thursday, November 1st. The stock was acquired at an average cost of $15.90 per share, with a total value of $249,630.00. Following the transaction, the chief executive officer now owns 151,247 shares of the company’s stock, valued at $2,404,827.30. The disclosure for this purchase can be found here. Insiders purchased 54,785 shares of company stock valued at $871,726 in the last three months. 3.88% of the stock is currently owned by company insiders.

Several institutional investors have recently modified their holdings of the company. MetLife Investment Advisors LLC boosted its position in Insmed by 12.4% during the second quarter. MetLife Investment Advisors LLC now owns 37,652 shares of the biopharmaceutical company’s stock valued at $890,000 after purchasing an additional 4,160 shares during the last quarter. AQR Capital Management LLC boosted its position in Insmed by 4.4% during the third quarter. AQR Capital Management LLC now owns 103,376 shares of the biopharmaceutical company’s stock valued at $2,090,000 after purchasing an additional 4,373 shares during the last quarter. NumerixS Investment Technologies Inc acquired a new stake in Insmed during the second quarter valued at $122,000. Pacer Advisors Inc. acquired a new stake in Insmed during the third quarter valued at $155,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Insmed during the second quarter valued at $200,000.

Insmed Company Profile

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex.

Read More: Bollinger Bands

Get a free copy of the Zacks research report on Insmed (INSM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply